Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report
Kelmendi B, Kichuk S, DePalmer G, Maloney G, Ching T, Belser A, Pittenger C. Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. Heliyon 2022, 8: e12135. PMID: 36536916, PMCID: PMC9758406, DOI: 10.1016/j.heliyon.2022.e12135.Peer-Reviewed Original ResearchObsessive-compulsive disorderTreatment of OCDPsychedelic treatmentTreatment-resistant obsessive-compulsive disorderRefractory obsessive-compulsive disorderOCD symptomsPsychological effectsSerotonin systemSingle experimental studyRecreational usersBrain serotonin systemTreatment of patientsClassic psychedelicsQuality of lifePsilocybinSymptomatic improvementCase reportClinical dataTherapeutic potentialEmotionsPatientsDisordersTreatmentNumber of conditionsCompulsionModels of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model
Brennan W, Belser A. Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model. Frontiers In Psychology 2022, 13: 866018. PMID: 35719571, PMCID: PMC9201428, DOI: 10.3389/fpsyg.2022.866018.Peer-Reviewed Original ResearchClinical trialsEvidence-based therapiesPsychedelic-Assisted PsychotherapyPsychiatric indicationsPAP treatmentTreatment outcomesTherapeutic benefitDrug AdministrationPsychedelic treatmentSupportive psychotherapyTherapeutic interventionsStudy therapistsPsychedelic medicineTreatmentTherapist interventionsCurrent standardClinical domainsClinical orientationTherapist trainingTrialsTherapeutic changeResearch standardizationTherapy modelInterventionCurrent article briefly